United States - English - NLM (National Library of Medicine)

eon labs, inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - carisoprodol 200 mg - carisoprodol, aspirin and codeine phosphate tablets, usp are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. limitations of use carisoprodol, aspirin and codeine phosphate tablets, usp should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration (see dosage and administration ). carisoprodol, aspirin and codeine phosphate tablets are contraindicated for: • all children younger than 12 years of age (see warnings) • post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy (see warnings ). carisoprodol, aspirin and codeine phosphate tablets are also contraindicated in patients with: carisoprodol, aspirin, and codeine phosphate tablets contains codeine. codeine in combination with carisoprodol and aspirin is a schedule iii

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - carisoprodol 200 mg - carisoprodol, aspirin and codeine phosphate tablets, usp are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses (seewarnings ), reserve carisoprodol, aspirin and codeine phosphate tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia carisoprodol, aspirin and codeine phosphate tablets,usp should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration (see dosage and administration ). carisoprodol, aspirin and codeine phosphate tablets are contraindicated for: - all children

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - carisoprodol 200 mg - carisoprodol and aspirin is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol and aspirin should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration (see dosage and administration ). carisoprodol and aspirin is contraindicated in patients with a history of: - a serious gi complication (i.e., bleeding, perforations, obstruction) due to aspirin use - aspirin induced asthma (a symptom complex which occurs in patients who have asthma, rhinosinusitis, and nasal polyps who develop a severe, potentially fatal bronchospasm shortly after taking aspirin or other nsaids) - hypersensitivity reaction to carbamate such as meprobamate - acute intermittent prophyria the efficacy, safety, and pharmacokinetics of carisoprodol and aspirin in pediatric patients less than 16 years

United States - English - NLM (National Library of Medicine)

avet pharmaceuticals inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - carisoprodol 200 mg - carisoprodol and aspirin tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol and aspirin tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration (see dosage and administration ). carisoprodol and aspirin tablets are contraindicated in patients with a history of: - a serious gi complication (i.e., bleeding, perforations, obstruction) due to aspirin use - aspirin induced asthma (a symptom complex which occurs in patients who have asthma, rhinosinusitis, and nasal polyps who develop a severe, potentially fatal bronchospasm shortly after taking aspirin or other nsaids) - hypersensitivity reaction to a carbamate such as meprobamate - acute intermittent porphyria controlled substance carisoprodol and aspirin tablets contain carisoprodol, a sche

United States - English - NLM (National Library of Medicine)

eon labs, inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - carisoprodol 200 mg - carisoprodol and aspirin tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol and aspirin tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration (see dosage and administration). carisoprodol and aspirin tablets are contraindicated in patients with a history of: controlled substance carisoprodol, a schedule iv controlled substance. carisoprodol has been subject to abuse, misuse, and criminal diversion for nontherapeutic use (see warnings ). abuse abuse of carisoprodol poses a risk of overdosage which may lead to death, cns and respiratory depression, hypotension, seizures and other disorders (see warnings ). patients at high risk of carisoprodol abuse may include those with prolonged use of carisoprodol, with a history of drug abuse, or tho

United States - English - NLM (National Library of Medicine)

rebel distributors corp - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - carisoprodol 200 mg - carisoprodol and aspirin tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of pain, muscle spasm, and limited mobility associated with acute, painful musculoskeletal conditions. acute intermittent porphyria; bleeding disorders; allergic or idiosyncratic reactions to carisoprodol, aspirin, or related compounds. abuse: in clinical use, abuse has been rare. dependence: in clinical use, dependence with carisoprodol and aspirin tablets have been rare and there have been no reports of significant abstinence signs, nevertheless, the following information on the individual ingredients should be kept in mind. carisoprodol: in dogs, no withdrawal symptoms occurred after abrupt cessation of carisoprodol from dosages as high as 1 gm/kg/day. in a study in man, abrupt cessation of 100 mg/kg/day (about five times the recommended daily adult dosage) was followed in some subjects by mild withdrawal symptoms such as abdominal cramps, insomnia, chills, headache and nausea. delir

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - carisoprodol, aspirin and codeine phosphate tablets, usp are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses (see warnings ), reserve carisoprodol, aspirin and codeine phosphate tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): -   have not been tolerated, or are not expected to be tolerated, -   have not provided adequate analgesia, or are not expected to provide adequate analgesia carisoprodol, aspirin and codeine phosphate tablets, usp should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration (see dosage and administration ). carisoprodol, aspirin and codeine phosphate tablets are contraindicated for: -   all

United States - English - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 350 mg - carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [see dosage and administration (2)]. carisoprodol tablets are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. there are no data on the use of carisoprodol during human pregnancy. animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. the primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increased risk for particular c

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 350 mg - carisoprodol tablets usp are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol tablets usp should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [see dosage and administration (2) ]. carisoprodol tablets are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. pregnancy category c.  there are no data on the use of carisoprodol during human pregnancy. animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. the primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamat

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 350 mg - carisoprodol tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [see dosage and administration (2) ]. carisoprodol tablets are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reactions to a carbamate such as meprobamate there are no data on the use of carisoprodol tablets during human pregnancy. animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. the primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increase